Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose Of Review: Prediabetes, or dysglycemia in the absence of diabetes, is a prevalent condition typically defined by a glycated hemoglobin (HgbA1c) of 5.7- < 6.5%. This article reviews current contemporary data examining the association between prediabetes and cardiovascular disease (CVD) as well as HgbA1c as a continuous measure of cardiovascular risk across the glycemic spectrum.
Recent Findings: Dysglycemia in the prediabetic range is associated with an increased risk of both subclinical and clinical CVD, including atherosclerotic CVD, chronic kidney disease, and heart failure. Several recent large, prospective studies demonstrate roughly linear risk with increasing HgbA1c, even below the threshold for prediabetes. "High-risk" patients with prediabetes have similar CVD risk as those with diabetes. HgbA1c below the threshold for diabetes stratifies CVD risk. Use of HgbA1c as a continuous measure, rather than simply dichotomized, may inform current and future prevention strategies. Given the high population attributable risk associated with prediabetes, targeted prevention strategies in this population warrant dedicated study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11883-022-01024-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spiritual interventions, including meditation, prayer, mindfulness, and compassionate care, have gained increasing attention for their potential to enhance both psychological resilience and overall health. This systematic review and meta-analysis examined eight eligible studies conducted across the USA, Europe, and China to assess the impact of such interventions on key outcomes, namely anxiety reduction, quality of life, chronic disease symptom management, and patient satisfaction. Seven studies contributed quantitative data.
View Article and Find Full Text PDFAppRaise: Software for Quantifying Evidence Uncertainty in Systematic Reviews Using a Posterior Mixture Model.
J Eval Clin Pract
September 2025
Health Technology Assessment Unit, Acute and Hospital-Based Care Portfolio, Ontario Health, Toronto, Ontario, Canada.
Rationale: Systematic reviews are essential for evidence-based healthcare decision-making. While it is relatively straightforward to quantitatively assess random errors in systematic reviews, as these are typically reported in primary studies, the assessment of biases often remains narrative. Primary studies seldom provide quantitative estimates of biases and their uncertainties, resulting in systematic reviews rarely including such measurements.
View Article and Find Full Text PDFClinical Outcomes and Complications of Basal, Bolus, and Combination Insulin Regimens in Type 2 Diabetes Mellitus: Evidence from Published Case Reports.
Diabetes Metab Syndr Obes
September 2025
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Insulin therapy remains a cornerstone in the management of type 2 diabetes mellitus (T2DM), especially in patients experiencing progressive loss of pancreatic beta-cell function or those with inadequate glycemic control despite oral antidiabetic therapy. This review synthesized clinical outcomes from 44 peer-reviewed case reports published between 2019 and 2024, identified through systematic searches in PubMed and Scopus. The included cases involved 15 males and 29 females, with patient ages ranging from 11 to 91 years (mean 53 ± 20.
View Article and Find Full Text PDFPrevalence and Associated Factors of Hypoglycemia Among Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study.
Cureus
August 2025
Department of Family Medicine, Akram and Rasool Hospital, Sarai Alamgir, PAK.
Background: Patients with type 2 diabetes mellitus (T2DM) often experience hypoglycemia, an underappreciated consequence that has a major negative influence on treatment compliance and quality of life.
Objective: This study aimed to determine the prevalence and associated factors of hypoglycemia among patients with T2DM, with a focus on treatment types, comorbidities, and glycemic control. By providing population-specific data, the study intends to inform clinical decision-making and contribute to safer, more personalized diabetes management strategies.
Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis.
EClinicalMedicine
October 2025
Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established treatments for obesity. However, it remains inconclusive whether the combination of lifestyle modifications and GLP-1RA interventions can lead to greater weight loss and better control of cardiovascular biomarkers. We aimed to evaluate the efficacy of this combination therapy on weight loss and cardiometabolic markers in adults with overweight or obesity.
View Article and Find Full Text PDF